Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat.
Certain chemokines inhibit HIV replication through binding to cell surface receptors which also act as viral coreceptors. Based on our previous observations that HIV-1 Tat can interact with alpha- and beta-chemokine receptors, we investigated the potential effect of extracellular Tat (ecTat) on infection and replication of CCR5-dependent (R5) and CXCR4-using (X4) HIV-1 strains in primary activated peripheral blood mononuclear cells (PBMC) of uninfected donors. Receptor desensitization and binding competition studies were used to determine chemokine receptor binding by ecTat. Standard HIV replication assays based on reverse transcriptase (RT) activity determination in culture supernatants of PBMC and real time PCR for HIV-1 gag DNA were used to determine potential effects on early (entry or RT) steps of infection. ecTat bound to CXCR4 expressing monocytes and mitogen-activated PBMC, and competed with the natural ligand of CXCR4, SDF-1alpha (stromal cell-derived factor-1alpha) in calcium mobilization assays. EcTat inhibited replication of the X4 HIV-1 (LAI/IIIB strain) in activated PBMC at concentrations close to those of SDF-1alpha, whereas it only modestly interfered with R5 HIV-1 (BaL) replication in PBMC. Both SDF-1alpha and ecTat inhibited accumulation of X4 HIV-1 gag DNA, indicating interference with viral entry and/or RT. Our data show the surprising and counter-intuitive observation that ecTat selectively represses X4 HIV replication. This could favour spreading of R5 viruses, a condition observed in vivo immediately after transmission and in the early asymptomatic phase of infection.
Ghezzi
S
S
AIDS Immunopathogenesis Unit, San Raffaele Scientific Institute, Milan, Italy.
Noonan
D M
DM
Aluigi
M G
MG
Vallanti
G
G
Cota
M
M
Benelli
R
R
Morini
M
M
Reeves
J D
JD
Vicenzi
E
E
Poli
G
G
Albini
A
A
D002118:Calcium / Q000378:metabolism; D002478:Cells, Cultured; D004279:DNA, Viral / Q000032:analysis; D015696:Gene Products, tat / Q000378:metabolism / Q000494:pharmacology*; D018023:HIV Seronegativity; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D007963:Leukocytes, Mononuclear / Q000276:immunology* / Q000821:virology*; D009000:Monocytes / Q000276:immunology* / Q000821:virology*; D010446:Peptide Fragments / Q000494:pharmacology; D019718:Receptors, CXCR4 / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D054322:tat Gene Products, Human Immunodeficiency Virus
D004279:DNA, Viral; D015696:Gene Products, tat; D010446:Peptide Fragments; D019718:Receptors, CXCR4; D054322:tat Gene Products, Human Immunodeficiency Virus; D002118:Calcium